Discounted Cash Flow (DCF) Analysis Unlevered

BiondVax Pharmaceuticals Ltd. (BVXV)

$1.36

+0.01 (+0.74%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 1.36 | undervalue

Operating Data

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 1.36
Beta 2.366
Diluted Shares Outstanding 754,076.41
Cost of Debt
Tax Rate 90.84
After-tax Cost of Debt -2.24%
Risk-Free Rate
Market Risk Premium
Cost of Equity 15.794
Total Debt 21.54
Total Equity 1,025,543.91
Total Capital 1,025,565.46
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 0.00%-13.66%591.91%-27.09%90.84%128.40%128.40%128.40%128.40%128.40%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -23.73-7.43-6.13-0.43-0.84-----
UFCF ----------
WACC
PV UFCF ------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 15.79
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt 7.47
Equity Value -
Shares Outstanding 754,076.41
Equity Value Per Share -